Prognostic factors in gastric cancer

被引:29
作者
Allgayer, H [1 ]
Heiss, MM [1 ]
Schildberg, FW [1 ]
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Surg, D-81377 Munich, Germany
关键词
D O I
10.1002/bjs.1800841206
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Despite gastric cancer being common, its prognosis has not been improved significantly in recent years. Now, greater insight has been gained into the biological properties of tumour cells, how they become malignant and what mechanisms they may use to invade and metastasize. This involves tumour-associated protease systems, loss or mutation of adhesion molecules and changes in genetics. The view of gastric cancer is changing: it is not only a solid tumour but also exhibits a minimal residual disease component even in the early stages of disease. Such biological tumour characteristics may provide new prognostic factors and also potential new therapeutic options. Methods This is an update of prognostic factors in gastric cancer, emphasizing new biological features, some of which have been investigated by this group over the past few years. Current results are discussed in the light of 212 references obtained from the Medline database from 1979 to 1997. Results There is high probability that some of the factors reviewed, such as c-erbB-2, individual course and phenotyping of disseminated tumour cells will become significant new prognostic variables. This is true also, to a lesser extent, of cathepsin D, matrix metalloproteinase 2 combined with activators or tissue inhibitor of metalloproteinases 2, CD44, E-cadherin, p53 and cripto. Plasminogen activator inhibitor 1 (PAI-1), a member of the urokinase-type plasminogen activator (uPA) system, can already be defined as an established new prognostic factor in gastric cancer. Conclusion PAI-1 should be considered prognostically in addition to established tumour classifications. Moreover, the uPA, system is a target for future therapeutic concepts. Further analysis of factors describing tumour biology should lead to new, functionally orientated, tumour classifications in gastric cancer.
引用
收藏
页码:1651 / 1664
页数:22
相关论文
共 228 条
[61]  
GRIGIONI WF, 1994, MODERN PATHOL, V7, P220
[62]   A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS [J].
GUNTHERT, U ;
HOFMANN, M ;
RUDY, W ;
REBER, S ;
ZOLLER, M ;
HAUSSMANN, I ;
MATZKU, S ;
WENZEL, A ;
PONTA, H ;
HERRLICH, P .
CELL, 1991, 65 (01) :13-24
[63]  
HAN HJ, 1993, CANCER RES, V53, P5087
[64]   BIOLOGY OF TUMOR-METASTASIS [J].
HART, IR ;
SAINI, A .
LANCET, 1992, 339 (8807) :1453-1457
[65]   NORWEGIAN MULTICENTER STUDY OF SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS UNDERGOING CURATIVE RESECTION FOR GASTRIC-CARCINOMA [J].
HAUGSTVEDT, TK ;
VISTE, A ;
EIDE, GE ;
SOREIDE, O .
BRITISH JOURNAL OF SURGERY, 1993, 80 (04) :475-478
[66]   A HUMAN HOMOLOG OF THE RAT METASTASIS-ASSOCIATED VARIANT OF CD44 IS EXPRESSED IN COLORECTAL CARCINOMAS AND ADENOMATOUS POLYPS [J].
HEIDER, KH ;
HOFMANN, M ;
HORS, E ;
VANDENBERG, F ;
PONTA, H ;
HERRLICH, P ;
PALS, ST .
JOURNAL OF CELL BIOLOGY, 1993, 120 (01) :227-233
[67]   The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer [J].
Heiss, MM ;
Babic, R ;
Allgayer, H ;
Gruetzner, KU ;
Jauch, KW ;
Loehrs, U ;
Schildberg, FW .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1996, 22 (01) :74-77
[68]  
Heiss MM, 1997, INFUSIONSTHERAPIE, V24, P20
[69]   TUMOR-ASSOCIATED PROTEOLYSIS AND PROGNOSIS - NEW FUNCTIONAL RISK-FACTORS IN GASTRIC-CANCER DEFINED BY THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR SYSTEM [J].
HEISS, MM ;
BABIC, R ;
ALLGAYER, H ;
GRUETZNER, KU ;
JAUCH, KW ;
LOEHRS, U ;
SCHILDBERG, FW .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2084-2093
[70]   BENEFICIAL EFFECT OF AUTOLOGOUS BLOOD-TRANSFUSION ON INFECTIOUS COMPLICATIONS AFTER COLORECTAL-CANCER SURGERY [J].
HEISS, MM ;
MEMPEL, W ;
JAUCH, KW ;
DELANOFF, C ;
MAYER, G ;
MEMPEL, M ;
EISSNER, HJ ;
SCHILDBERG, FW .
LANCET, 1993, 342 (8883) :1328-1333